NCT00722332View on ClinicalTrials.gov

Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Hepatitis BLiver Transplantation
Interventions
BIOLOGICAL

HepaGam B

Hepatitis B Immunoglobulin

Trial Locations (16)

10016

New York

10029

New York

10032

New York

15213

Pittsburgh

30322

Atlanta

44195

Cleveland

55455

Minneapolis

60611

Chicago

75246

Dallas

77030

Houston

90033

Los Angeles

90095

Los Angeles

94304

Palo Alto

01805

Burlington

07101

Newark

H2X3J4

Montreal

Sponsors
All Listed Sponsors
lead

Cangene Corporation

INDUSTRY

NCT00722332 - Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients | Biotech Hunter | Biotech Hunter